A Combination Study to Determine the Safety and Efficacy of Panzem NCD With Avastin in Metastatic Carcinoid Tumors
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
This single center, open-label study will evaluate the safety and efficacy of Panzem
(2-methoxyestradiol, 2ME2) Nanocrystal Dispersion (NCD) administered orally with recombinant
human monoclonal antibody against vascular endothelial growth factor (bevacizumab)
administered intravenously, in patients with locally advanced or metastatic carcinoid tumors.